Showing 2891-2900 of 5646 results for "".
- CHOP Researchers Develop Highly Specific Predictive Screening Tool for Retinopathy in Premature Infantshttps://modernod.com/news/chop-researchers-develop-highly-specific-predictive-screening-tool-for-retinopathy-in-premature-infants/2480024/A multi-hospital collaboration led by researchers at Children’s Hospital of Philadelphia (CHOP) has found a simple method of determining which premature infants should be screened for retinopathy of prematurity (ROP). The recommendations have the potential t
- Novartis Exits Antibacterial, Antiviral Researchhttps://modernod.com/news/novartis-exits-antibacterial-antiviral-research/2480028/Novartis will close its antibacterial and antiviral research operations in Emeryville, California as part of CEO Vas Narasimhan’s plans to narrow the drugmaker’s R&D focus. Spokesman Ryan McBride said while “there is a commercial market for these medicines…we do not believe
- Ocular Therapeutix Announces NDA Resubmission of Dextenzahttps://modernod.com/news/ocular-therapeutix-announces-nda-resubmission-of-dextenza/2480054/Ocular Therapeutix has announced the resubmission of the company’s new drug application (NDA) to the FDA for its lead product candidate Dextenza (dexamethasone insert) 0.4mg, for the treatment of ocular pain following ophthalmic surgery. The resubmission is intended to address manufacturing defic
- Novartis Announces Intention to Spinoff Alcon Into Standalone Companyhttps://modernod.com/news/novartis-announces-intention-to-spinoff-alcon-and-launch-a-5-billion-share-buyback/2480055/After months of speculation, Novartis confirmed on Friday its intention to spinoff Alcon into a separately-traded standalone company. The major transaction would enable Novartis to focus on bringing new drugs to market, while allowing Alcon to focus on its core offerings in the surgical and visio
- Retinal Thinning Tied to Cognitive Declinehttps://modernod.com/news/retinal-thinning-tied-to-cognitive-decline/2480058/Thinning of the eye’s retinal nerve fiber layer (RNFL) appears to be a strong predictor of cognitive decline, new research shows, according to a report in Medscape. Investigators found healthy individuals with RNFL thinning w
- Novaliq’s NovaTears Treatment for Evaporative Dry Eye Disease is Now Available across Australia and New Zealandhttps://modernod.com/news/novaliqs-novatears-treatment-for-evaporative-dry-eye-disease-is-now-available-across-australia-and-new-zealand/2480059/Novaliq announced that NovaTears, a novel topical treatment of dry eye disease and meibomian gland dysfunction (MGD), is now also available in Australia. Just 8 months after launching in New Zealand, AFT Pharmaceuticals Ltd (AFT) has achieved registration of NovaTears in Australia. AFT, a
- Oyster Point Pharma Gets Green Light From FDA to Proceed With Clinical Development of Dry Eye Treatmenthttps://modernod.com/news/oyster-point-pharma-gets-green-light-from-fda-to-proceed-with-clinical-development-of-dry-eye-treatment/2480060/Oyster Point Pharma announced that the FDA has cleared the company’s investigational new drug (IND) application to proceed with clinical development of OC-01, an investigational compound intended to stimulate natural tear film production in people with dry eye disease that is administered with a
- Bausch + Lomb Announces Licensing Agreement With Tangible Science for Use of Hydra-Peg Custom Contact Lens Coatinghttps://modernod.com/news/bausch-lomb-announces-licensing-agreement-with-tangible-science-for-use-of-hydra-peg-custom-contact-lens-coating/2480063/Bausch + Lomb announced that it has entered into a worldwide licensing agreement with Tangible Science, allowing Bausch + Lomb to offer the Tangible Hydra-PEG advanced contact lens coating technology for use with several of its Boston gas permeable (GP) materials and scleral lenses. Terms
- Kala Pharmaceuticals Announces Update to KPI-121 0.25% Development Planhttps://modernod.com/news/kala-pharmaceuticals-announces-update-to-kpi-121-0-25-development-plan/2480081/Kala Pharmaceuticals provided an update on the development plan for KPI-121 0.25%, which if approved could be the first FDA-approved product for the short-term treatment of dry eye disease.
- SynergEyes and Brien Holden Vision Institute Join Forces for Specialty Contact Lens Developmenthttps://modernod.com/news/synergeyes-and-brien-holden-vision-institute-join-forces-for-specialty-contact-lens-development/2480098/SynergEyes announced a new partnership with the Brien Holden Vision Institute, a translational vision correction center that delivers advanced, customized vision correction for myopes and presbyopes. The exclusive worldwide licensing agreement will enable the manufacturing of design technologies